Wyeth and ViroPharma have decided to discontinue development of their hepatitis C drug HCV-796, after concerns about hepatotoxicity were raised during a Phase II trial last year.
CEO of ViroPharma Vincent Milano commented that "significant activities were undertaken to determine a clear path forward for HCV-796; however, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development." ViroPharma also stated that the two companies do not plan to collaborate on future development of hepatitis C drugs
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment